Ttr (Transthyretin) Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Ttr (Transthyretin) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@alzheimers]
Transthyretin (TTR) is a 55.9 kDa homotetrameric protein composed of four identical subunits (14 kDa each). Each monomer contains:
Seven β-strands forming a β-sandwich fold
Two α-helices
A central channel that binds thyroid hormone (T4) and retinol-binding protein
Quaternary structure:
Tetrameric assembly is essential for function
Monomers can dissociate and misfold
Amyloidogenic mutations destabilize the tetramer
Normal Function
...
TTR (Transthyretin) Protein
Overview
Ttr (Transthyretin) Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Ttr (Transthyretin) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@alzheimers]
Carpal tunnel syndrome: Often an early manifestation
Spinal stenosis: TTR deposits in ligaments
Alzheimer's Disease
TTR may bind [Aβ](/proteins/amyloid-beta) and modulate its aggregation
TTR expression is altered in AD
May have protective role against Aβ toxicity
Parkinson's Disease
TTR can form amyloid inclusions in some PD cases
Role in Lewy body pathology is unclear
Therapeutic Targeting
Tetramer Stabilizers (FDA Approved)
Tafamidis (Vyndaqel): TTR stabilizer, approved for FAP
Diflunisal: NSAID that stabilizes TTR
Nitisinone: Reduces TTR production
Gene Silencing (FDA Approved)
Patisiran (Onpattro): siRNA targeting TTR
Vutrisiran (Amvuttra): siRNA (subcutaneous)
Inotersen (Tegsedi): Antisense oligonucleotide
Gene Editing
CRISPR-based approaches in development
Key Publications
Saraiva MJ, et al. (1989). "Molecular cloning of a complementary DNA encoding the plasma protein transthyretin." J Clin Invest. 84(3):907-913.
H逆 BA, et al. (2003). "Transthyretin: a villain in amyloid angiopathy." J Neuropathol Exp Neurol. 62(12):1291-1299.
Johnson SM, et al. (2012). "Native state stabilization by NSAIDs or tafamidis prevents misfolding." Nat Chem Biol. 8(7):639-645.
Overview
Ttr (Transthyretin) Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Ttr (Transthyretin) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.